The effect of adding Agomelatine to Escitalopram in the treatment of depression

The effect of adding Agomelatine to Escitalopram in the treatment of major depressive disorder

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130311012782N52

Enrollment

Registered

2021-02-24

Start date

2021-04-04

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder. Major Depressive Disorder

Interventions

Intervention 1: Intervention group 1: Receive 25-50 mg oral Agomelatine of Abidi Pharmaceutical Company as a single daily dose and 10-20 mg of oral Escitalopram made by abidi Pharmaceutical Company as

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Major Depressive Disorder Patient consent to participate in the study range age between 18-65 years Minimum literacy Has suitable conditions for completing the questionnaire

Exclusion criteria

Exclusion criteria: Drug addiction Having medical and underlying disease Major changes in diet regimen in recent months Existence of verbal and hearing problems

Design outcomes

Primary

Measure	Time frame
Treatment of Major Depressive Disorder. Timepoint: Every month. Method of measurement: Hamilton questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Bidaki

Yazd University of Medical Sciences

reza.bidaki111@gmail.com+98 35 3726 3733

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026